PHAT - Prakiraan wutah bathi kanggo taun ngarep phathompharma.com

The expected annual EPS growth rate for the coming year reflects a trend where 189.00 becomes the new value for this metric. Phathom Pharmaceuticals (PHAT) attracts leading scientists and managers through stock options and startup drive. Business profitability relies on the expansion of insurance coverage and Voquezna sales. Simultaneously, the company is implementing automated packaging and digital document management to accelerate clinical trials.

PHAT: Prakiraan wutah bathi kanggo taun ngarep Phathom 04.07.2022 - 14.11.2026

phathompharma.com - rincian analitis lan metrik utama (PHAT)

- rega lan prakiraan konsensus rega:

Bagan rega Phathom Corp|PHAT - Bagan tingkat prakiraan

- statistik kapitalisasi pasar:

Kapitalisasi pasar Phathom Pharmaceuticals|PHAT - Nilai Dipunlarasaken Utang lan Kas

- indikator kapitalisasi buku:

Nilai Buku saben Saham Phathom Pharmaceuticals|PHAT - Kapitalisasi Buku|Rasio Kapitalisasi marang Aset Bersih phathompharma.com|PHAT - Aset Agregat Bisnis

- indikator total utang lan likuiditas perusahaan:

Total Utang marang Modal Phathom Pharmaceuticals|PHAT - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Phathom Pharmaceuticals, Inc.|PHAT - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Phathom Pharmaceuticals|PHAT - Kewajiban jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Phathom Pharmaceuticals|Likuiditas cepet phathompharma.com

- informasi bathi lan kelipatan valuasi:

PHAT - Bathi sawise pajeg|Proyeksi bathi mangsa ngarep Phathom Pharmaceuticals|PHAT - Nilai perusahaan marang bathi resik|Pangali Forward P/E Phathom Pharmaceuticals|PHAT - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Phathom Pharmaceuticals|PHAT - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Phathom Pharmaceuticals|PHAT - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan phathompharma.com|PHAT - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Phathom Pharmaceuticals

- data pendapatan lan penerimaan dodolan:

PHAT - Dodolan perusahaan|Prakiraan volume dodolan Phathom Corp|PHAT - Rega marang dodolan|Multiplikator forward rega marang pendapatan Phathom Pharmaceuticals

Analisis fundamental perusahaan:PHAT, Phathom Corp

Produk dadi Phathom Pharmaceuticals, Inc.

Investors must weigh the resilience of the Phathom Pharmaceuticals (PHAT) business model against the pressure of insurance pricing policies and competition within the GI segment. By analyzing the projected net income per share growth for the coming year, one can assess the consensus EPS forecast, which reflects the company's ability to monetize new drugs and achieve operational profitability despite market risks.

Analisis perusahaan pesaing

Prakiraan wutah bathi resik saben saham kanggo taun ngarep Terns Pharmaceuticals Inc|Ironwood Pharmaceuticals Inc - Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep|Prakiraan wutah bathi kanggo taun ngarep CURX|IMRN (immuron.com.au) - Dinamika bathi saben saham sing diarepake ing taun ngarep|Prakiraan wutah bathi kanggo taun ngarep EVOK (Evoke Pharma)|Prakiraan wutah bathi kanggo taun ngarep Entero Therapeutics Inc. ENTO|RDHL: Prakiraan wutah bathi saben saham kanggo taun ngarep|Palisade Bio Inc. - Proyeksi tambahing bathi saben saham ing taun ngarep|JAGX: Prakiraan wutah bathi kanggo taun ngarep|bioratherapeutics.com - Dinamika bathi saben saham sing diarepake ing taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Morphic